Real-world study on the efficacy of Polyene phosphatidylcholine capsules as adjunctive therapy for chronic hepatitis B
- VernacularTitle:多烯磷脂酰胆碱胶囊辅助治疗慢性乙型肝炎有效性的真实世界研究
- Author:
Baoqiang ZHU
1
,
2
;
Qi HU
3
;
Qiang LIU
3
,
4
;
Meiding WANG
4
;
Enwu LONG
1
Author Information
1. Dept. of Pharmacy/Personalized Drug Therapy Key Laboratory of Sichuan Province，Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital/the Affiliated Hospital of University of Electronic Science and Technology of China，Chengdu 610072，China
2. Dept. of Pharmacy，the First People’s Hospital of Shuangliu District/West China （Airport） Hospital of Sichuan University，Chengdu 610200，China
3. Dept. of Pharmacy，Hospital of Chengdu University of Traditional Chinese Medicine，Chengdu 610072，China
4. School of Pharmacy，Southwest Medical University，Sichuan Luzhou 646000，China
- Publication Type:Journal Article
- Keywords:
Polyene phosphatidylcholine capsule;
hepatoprotective drug;
chronic hepatitis B;
alanine transaminase;
propensity
- From:
China Pharmacy
2024;35(20):2505-2511
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the effectiveness of Polyene phosphatidylcholine capsules （PPC） as adjuvant therapy for chronic hepatitis B （CHB）. METHODS Retrospective data were collected from the patients diagnosed with CHB， treated with hepatoprotective drugs combined with antiviral drugs or antiviral drugs alone， and underwent long-term follow-up in the outpatient department of Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital from January 1， 2017 to December 31， 2022. After balancing confounding factors through propensity score matching， the effectiveness of PPC combined with antiviral therapy versus antiviral therapy alone （PPC+antiviral group versus antiviral group） and PPC+Diammonium glycyrrhizinate enteric- coated capsules （DGC） combined with antiviral therapy versus DGC combined with antiviral therapy （PPC+DGC+antiviral group versus DGC+antiviral group） as therapy for CHB were compared under real medical conditions. RESULTS Totally 382 patients with CHB who received hepatoprotective agents based on antiviral therapy （221， 63 and 98 patients who received DGC， PPC and combination therapy， respectively） and 400 patients who received antiviral therapy alone were ultimately included. After propensity score matching， there were 47 patients each in the PPC+antiviral group and the antiviral group， respectively； after treatment， the alanine transaminase （ALT） levels in the PPC+antiviral group were significantly reduced compared to before treatment and the antiviral group at the same time （P＜0.05）， while there was no statistically significant difference in the ALT normalization rate between the two groups （P＞0.05）. There were 74 patients each in the PPC+DGC+antiviral group and the DGC+antiviral group， respectively； after treatment， the ALT levels of patients in both groups were significantly reduced compared to before treatment， the ALT levels of PPC+DGC+antiviral group were significantly lower than those in the DGC+antiviral group at the same time， and the ALT normalization rate was significantly higher in the PPC+DGC+antiviral group than that in the DGC+antiviral group （P＜0.05）. CONCLUSIONS Based on using antiviral drugs to treat CHB， adjuvant therapy combined with PPC has a significant advantage in reducing liver enzymes； in addition， compared with the DGC combined antiviral regimen， the dual hepatoprotective drug of DGC and PPC combined with an antiviral regimen has better effects on liver protection and reduction of liver enzymes.
